Comparative pharmacoeconomic analysis of the use of Bonviva® (ibandronat) to prevent fractures in postmenopausal osteoporosis

Pyadushkina, E.; Gerasimova, K. V.; Goryainov, Sergey; Omelyanovskiy, V. V.; Avksentyeva, M. V.; Krysanov, I.

doi:10.14412/1996-7012-2012-771

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In numerous randomized clinical trials, drugs of this group, more than others, prevented occurrence of new and recurrent fractures. [5][6][7][8][9][10][11] Representatives of bisphosphonates improve prognosis of fractures due to their ability to significantly slow down the intensity of resorptive processes in bones, to affect bone remodeling, and to increase bone mineral density. Nitrogencontaining bisphosphonates of third generation ibandronic acid (Bonviva®) possess promising features for clinical practice.…”

Section: Introductionmentioning

confidence: 99%

Efficiency of Ibandronate in Monotherapy and in Combination with Alfacalcidol in Women with Postmenopausal Osteoporosis

Ismailov¹,

Abboskhuzhaeva²,

Alikhanova³

et al. 2016

Int J Biomed

View full text Add to dashboard Cite

The aim of this study was to carry out a comparative analysis of the efficiency of ibandronate monotherapy and combined therapies with ibandronate and alfacalcidol in women with postmenopausal osteoporosis.Materials and Methods: A total of 53 women (mean age 60.7 years) with postmenopausal osteoporosis (PMO) were randomized to monotherapy with ibandronate 150 mg/month (Group Ib) (n=25) and therapy with ibandronate 150 mg/month plus alpha-D 3 (AD3) 1μg (alfacalcidol) daily (Group Ib+AD3) (n=28). All women received calcium and vitamin D 3 supplements. Patients were recruited in one center and were followed up for 6 months on a monthly basis. To assess the efficacy of therapy, BMD was measured at LS (L1-L4) and PF at the beginning and end of therapy by DEXA. Biochemical markers of bone turnover were also assessed.Results: Statistically significant increases in BMD compared with baseline values and the control group were observed in both ibandronate treatment groups. Growth of BMD was significantly higher in Group Ib+AD3 compared to Group Ib. An assessment of CTX dynamics showed a notable decrease in CTX level in patients of both groups compared with levels before treatment. Generally, PTH level decreased insignificantly, but a more pronounced reduction was seen in Group Ib+AD3. TP1NP level significantly increased in Group Ib and was more pronounced in Group Ib+AD3.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficiency of Ibandronate in Monotherapy and in Combination with Alfacalcidol in Women with Postmenopausal Osteoporosis

Ismailov¹,

Abboskhuzhaeva²,

Alikhanova³

et al. 2016

Int J Biomed

View full text Add to dashboard Cite

show abstract

Economic burden of some age-related diseases

Arbatskiy

2023

jour

View full text Add to dashboard Cite

Background. One of the main concerns posed by implementing new biomedical technologies is the lack of a pharmacoeconomic justification for the economic effect or the burden of certain nosologies on the state budget. To date, the medical literature on age-related diseases focuses on diagnosis, pathogenesis, new methods of treatment and the results of prescribed treatment. However, assessing the economic burden of these diseases is equally important. Only for selected diseases, regular publications on the calculation of the economic effect and economic burden of diseases can be found. For less common diseases, there are single publications, the information from which is no longer relevant and requires regular updating and maintenance.Aim. To conduct an indicative assessment of the economic burden for the most common age-related diseases.Materials and methods. When preparing the publication, foreign and domestic sources containing economic information about the most common age-associated diseases were used.Annual reports of biopharmaceutical companies producing drugs for the treatment of age-related diseases were used to obtain an understanding of current developments in the treatment of these diseases. Additionally, data from Rosreestr (Russian Federal Service for State Registration, Cadastre and Cartography) were used for certain diseases.Results. According to the analyzed information, it has been found that age-related diseases are a significant economic burden for the healthcare system of the state. However, not all specialized medical organizations assess the economic burden associated with such diseases.Conclusion. As a result of analyzing the economic burden of the most common age-related diseases, the conclusion can be drawn that regular assessment of the economic burden for Alzheimer's disease, diabetes, chronic obstructive pulmonary disease, depression, atherosclerosis and osteoporosis is necessary

show abstract

Comparative pharmacoeconomic analysis of the use of Bonviva® (ibandronat) to prevent fractures in postmenopausal osteoporosis

Cited by 2 publications

References 27 publications

Efficiency of Ibandronate in Monotherapy and in Combination with Alfacalcidol in Women with Postmenopausal Osteoporosis

Efficiency of Ibandronate in Monotherapy and in Combination with Alfacalcidol in Women with Postmenopausal Osteoporosis

Economic burden of some age-related diseases

Contact Info

Product

Resources

About